See the DrugPatentWatch profile for Blenrep
What patent covers Blenrep (belantamab mafodotin), and who owns it?
The key patents that determine who can market belantamab mafodotin (Blenrep) and when generally sit in the patent families covering the antibody-drug conjugate (ADC) and its specific components and uses. Ownership is held by the drug’s originator and related technology holders, but the exact “Blenrep patent” depends on the specific patent number and jurisdiction you mean (for example, U.S. vs. Europe), because different patents expire on different dates.
If you tell me the country (U.S., UK, EU, etc.) or the patent number you’ve seen, I can narrow to the exact patent and its expiry.
When does the main Blenrep patent expire?
Patent expiry for Blenrep depends on:
- the specific patent in force (primary composition vs. formulation vs. methods of treatment),
- the jurisdiction (different filing and term calculations), and
- whether patent term adjustments, extensions, or regulatory exclusivity apply.
Because “Blenrep patent” usually refers to multiple different patents across a family, you typically get one headline date for the core patent and additional later dates for method/formulation-related patents. To give a precise expiry date, I need either the jurisdiction or the patent/publication number.
Can biosimilars or generic versions of Blenrep enter before patent expiry?
Blenrep is a complex antibody-drug conjugate (not a small molecule). That means “generic” entry rules don’t work the same way as for standard chemical generics, and developers often rely on biosimilar/biologic pathways plus their own manufacturing and regulatory packages.
Even if exclusivity is near expiration, entry can still be blocked by:
- remaining patents (composition or method claims),
- injunctions in specific jurisdictions, or
- additional exclusivities that extend market protection beyond the first patent expiry date.
A precise answer again depends on which patent family and which country you’re tracking.
What happens if a company launches Blenrep later using a “faster” pathway?
If another company seeks approval for a belantamab-like product (or a change intended to avoid specific claims), it may still face patent litigation or risk of infringement depending on what claims remain enforceable and how closely the product’s structure, linkers, drug payloads, or dosing regimen match what those patents cover.
Where this gets decided can be jurisdiction-specific and driven by the patent landscape at the time of launch.
Are there multiple “Blenrep patents” rather than one?
Yes. For ADCs like belantamab mafodotin, patent portfolios commonly include multiple layers, including:
- antibody/target binding aspects,
- linker/payload chemistry,
- conjugation process and manufacturing controls,
- formulations and stability,
- dosing regimens and clinical-use method claims.
So people searching “Blenrep patent” often bump into different expiration dates and different legal protections.
Which Blenrep-related patents should you look up (so you get the right expiry date)?
To avoid the common mismatch where you look at the wrong patent, searches usually focus on:
- the patent covering the core ADC composition,
- patents covering the specific payload/linker architecture,
- method-of-treatment claims tied to the labeled use, and
- country-specific registrations (because enforcement and term differ).
If you share the country or a patent number (or a link/screenshot text), I can pinpoint the exact patent and what it protects.
Tell me what you need next
Which country are you asking about (U.S., EU/EMA, UK, etc.), and do you mean a specific patent number or just the “main” Blenrep exclusivity/expiry date?